CytoGenix Announces Notice of Allowance in Australia for Single Stranded DNA Expression...

CytoGenix Announces Notice of Allowance in Australia for Single Stranded DNA Expression Vector Patent

HOUSTON--(Business Wire)--CytoGenix, Inc. (OTCBB:CYGX) announced today it has received a
notice of allowance for a patent on its original single stranded DNA
expression plasmid vectors in Australia. The patent, entitled
"Production of ssDNA in vivo," claims both compositions and methods
for using the single stranded DNA expression vectors. The subject
matter includes several variations of the expression vector system for
inducing cells to produce specifically designed single strands of DNA
which may be used in antisense, aptamer, triplex or DNA enzyme
applications. The claimed system provides a more advanced and flexible
approach for using the Company's proprietary ssDNA expression system.

"The award of this allowance provides further validation of
CytoGenix technology and improves the Company's ability to secure
strategic partners that can assist in commercialization of CytoGenix
products using this ssDNA expression system," stated Malcolm Skolnick,
CytoGenix President and Chief Executive Officer.

Dr. Yin Chen, Chief Scientific Officer and co-inventor of the
technology, comments, "This is a significant step forward for
CytoGenix because the technology has broad application in potential
therapeutics and high-throughput drug screening."

CytoGenix, Inc. is a Houston-based biopharmaceutical company
pioneering the new field of gene based medicine and is focused on
developing innovative vaccines and therapeutic products using its
three proprietary technology platforms: synDNA(TM) enzymatic,
non-bacterial production methodology, single stranded DNA (ssDNA)
expression, and oligonucleotide based anti-bacterial technologies.
CytoGenix currently holds 13 granted patents, 2 allowances, and 55
additional international or US patent applications claiming methods
and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the Company's filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology can be found on the website at
www.cytogenix.com.

CytoGenix, Inc., Houston
VP of Finance and Administration
Chief Financial Officer
Greg Taylor, 713-789-0070
or
Investor Relations
Parag Dave, 917-322-2585
pdave@otccommunications.com

Copyright Business Wire 2008